Free Trial

Azenta, Inc. (NASDAQ:AZTA) Shares Sold by Balyasny Asset Management L.P.

Azenta logo with Medical background

Balyasny Asset Management L.P. trimmed its stake in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 76.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,097 shares of the company's stock after selling 123,462 shares during the quarter. Balyasny Asset Management L.P. owned about 0.08% of Azenta worth $1,855,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in Azenta during the 4th quarter worth approximately $530,000. State of Alaska Department of Revenue lifted its holdings in shares of Azenta by 355.2% in the 4th quarter. State of Alaska Department of Revenue now owns 25,899 shares of the company's stock valued at $1,294,000 after buying an additional 20,210 shares during the period. Stephens Inc. AR acquired a new stake in shares of Azenta in the 4th quarter valued at approximately $313,000. Thrivent Financial for Lutherans lifted its holdings in shares of Azenta by 206.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 35,223 shares of the company's stock valued at $1,761,000 after buying an additional 23,731 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Azenta in the 4th quarter valued at approximately $813,000. 99.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Needham & Company LLC reduced their price target on Azenta from $59.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Evercore ISI raised their price target on Azenta from $50.00 to $52.00 and gave the company an "in-line" rating in a report on Thursday, February 6th. Finally, TD Cowen raised Azenta to a "hold" rating in a report on Thursday, February 27th.

Check Out Our Latest Stock Analysis on Azenta

Azenta Price Performance

NASDAQ AZTA opened at $28.30 on Tuesday. Azenta, Inc. has a 1-year low of $23.91 and a 1-year high of $63.58. The company has a market capitalization of $1.29 billion, a P/E ratio of -9.50 and a beta of 1.64. The business has a 50 day moving average price of $31.20 and a 200 day moving average price of $41.95.

Azenta (NASDAQ:AZTA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.04). Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. During the same period in the previous year, the company earned $0.06 earnings per share. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. On average, research analysts expect that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

Azenta Profile

(Free Report)

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Read More

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Azenta Right Now?

Before you consider Azenta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.

While Azenta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 AI ETFs for Steady Gains in 2025 (Without the Wild Volatility)
Goldman Sachs Warns of 20% Market Drop—Are They Right?
Top 3 Insider Stock Buys in April—Are They Still Good in May?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines